

**Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) - Global Forecast to 2028**

Market Report | 2023-09-05 | 374 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The global plasma fractionation market size is projected to reach USD 40.4 billion by 2028 from USD 29.0 billion in 2023, at a CAGR of 6.9% during the forecast period. Expanding the number of plasma collection centers allows market players to collect a larger volume of plasma from donors. This increased supply of raw materials becomes the foundation for producing a greater quantity of plasma-derived products, meeting the growing demand in the market. For instance, in December 2022, CSL Behring (Australia) announced the opening of a USD 900 million Plasma Fractionation Facility in Victoria, Australia. The new state-of-the-art facility can process up to 9.2 million plasma equivalent liters per annum.

"The hospitals and clinics segment is expected to dominate the market during the forecast period."

Based on end user, the plasma fractionation market is segmented into research laboratories, hospitals and clinics, and academic institutes. In 2022, the clinics and hospitals segment accounted for the largest share of the global plasma fractionation market. The growing number of hospitals and clinics in emerging and developed economies, as well as the improvement in healthcare infrastructure, are attributed to this segment's major share in the market. Leading companies in this market are collaborating with hospitals to conduct clinical trials and promote awareness about the use of plasma products in the treatment of rare diseases. The demand for plasma products for the treatment of many rare and life-threatening disorders like hemophilia, PID, and COVID-19 is anticipated to increase as a result of such initiatives by companies and hospitals.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

"The pulmonology application segment will witness the highest growth in the plasma fractionation market."

Based on application, the plasma fractionation market is segmented into hematology, critical care, pulmonology neurology, immunology, , hemato-oncology, rheumatology, and other applications. In 2022, the pulmonology segment is expected to register the highest CAGR during the forecast period. The two major plasma products used in the treatment of various respiratory disorders are immunoglobulins and protease inhibitors. The main functions of immunoglobulins are the prevention and treatment of upper and lower respiratory tract infections. The market for pulmonology applications has grown significantly in recent years due to the significant growth in the usage of protease inhibitors, such as alpha-1-antitrypsin.

"North America will dominate the market during the forecast period."

Based on region, the plasma fractionation market is further segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2022, North America accounted for the largest share of the plasma fractionation market, followed by Europe and the Asia Pacific. North America's dominance in the global market is due to the fact that top players are continuously engaged in adopting various organic and inorganic growth strategies such as collaborations, partnerships, and acquisitions to strengthen their market position. Major players in this industry in the area use the expansion of fractionation plants with cutting-edge technologies as a key growth strategy. The top competitors also focus on acquiring plasma collecting facilities to increase their market share in North America.

The primary interviews conducted for this report can be categorized as follows:

-□By Respondent: Supply Side - 70% and Demand Type - 30%

-□By Designation: Managers - 45%, Directors - 30%, and Executives - 25%

-□By Region: North America -25%, Europe -25%, Asia-Pacific -40%, Latin America-5%, Middle East -2.5% & Africa- 2.5%

List of Companies Profiled in the Report

-□CSL (Australia)

-□Takeda Pharmaceutical Company Limited (Japan)

-□Grifols, S.A. (Spain)

-□Octapharma AG (Switzerland)

-□Kedrion S.P.A (Italy)

-□LFB (France)

-□ADMA Biologics (US)

-□Sanquin (Netherlands)

-□China Biologic Products Holdings Inc. (China)

-□GC Pharma (Korea)

-□Hualan Bioengineering Co., Ltd. (China)

-□Japan Blood Products Organization (Japan)

-□Emergent BioSolutions (US)

-□Shanghai Raas Blood Products Co., Ltd. (China)

-□Intas Pharmaceuticals Ltd. (India)

-□Bharat Serum Vaccines Limited (India)

-□SK Plasma (Korea)

-□Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)

-□Kamada (Israel)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Centurion Pharma (Istanbul)
- Prothya Biosolutions (Netherlands)
- PlasmaGen BioSciences Pvt. Ltd. (India)
- Virchow Biotech Private Limited (India)
- Fusion Healthcare (India)
- Hemarus Therapeutics Limited (India)

**Research Coverage:**

This report provides a detailed picture of the plasma fractionation market. It aims at estimating the size and future growth potential of the market across different segments, such as the product, application, end-user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

**Reasons to Buy the Report:**

The report provides insights on the following pointers:

- Analysis of key drivers (growing use of immunoglobulins in various therapeutic areas, strategic expansion of plasma collection centers/inventories by market players, growing prevalence of respiratory diseases and AATD), restraints (high costs and limited reimbursements for plasma products, market disruption caused by recombinant alternatives), opportunities (government strategies increasing regional self-sufficiency), and challenges (stringent government regulations for maintaining safety and quality of plasma products) influencing the growth of the plasma fractionation market.

- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the plasma fractionation market.

- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various plasma fractionation facilities across key geographic regions.

- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the plasma fractionation market.

- Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players like CSL (Australia), Takeda Pharmaceutical Company Limited (Japan), Grifols, S.A. (Spain), Octapharma AG (Switzerland), Kedrion S.P.A (Italy), among others in the plasma fractionation market.

**Table of Contents:**

- 1 INTRODUCTION 50
- 1.1 STUDY OBJECTIVES 50
- 1.2 MARKET DEFINITION 50
- 1.2.1 INCLUSIONS AND EXCLUSIONS 50
- 1.3 MARKET SCOPE 51
- FIGURE 1 PLASMA FRACTIONATION MARKET SEGMENTATION 51
- 1.4 YEARS CONSIDERED 52
- 1.5 CURRENCY CONSIDERED 52
- 1.6 RESEARCH LIMITATIONS 52
- 1.7 STAKEHOLDERS 53
- 1.8 SUMMARY OF CHANGES 53
- 1.8.1 RECESSION IMPACT: PLASMA FRACTIONATION MARKET 54
- 2 RESEARCH METHODOLOGY 55

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.1	RESEARCH DATA	55	
	FIGURE 2	RESEARCH DESIGN	55
2.1.1	SECONDARY DATA	56	
2.1.2	PRIMARY DATA	56	
	FIGURE 3	PLASMA FRACTIONATION MARKET: BREAKDOWN OF PRIMARIES	57
2.2	MARKET SIZE ESTIMATION	58	
	FIGURE 4	MARKET SIZE ESTIMATION: SUPPLY SIDE ANALYSIS, 2022	58
	FIGURE 5	MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022	59
	FIGURE 6	ILLUSTRATIVE EXAMPLE OF CSL: REVENUE SHARE ANALYSIS, 2022	59
2.2.1	INSIGHTS FROM PRIMARY EXPERTS	60	
	FIGURE 7	MARKET GROWTH FACTORS VALIDATION FROM PRIMARY EXPERTS	60
	FIGURE 8	MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH	61
2.3	GROWTH FORECAST	62	
	FIGURE 9	PLASMA FRACTIONATION MARKET: CAGR PROJECTIONS, 2023-2028	62
	FIGURE 10	PLASMA FRACTIONATION MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	63
2.4	MARKET BREAKDOWN AND DATA TRIANGULATION	64	
	FIGURE 11	DATA TRIANGULATION METHODOLOGY	64
2.5	STUDY ASSUMPTIONS	65	
2.6	RISK ANALYSIS	65	
2.7	RECESSION IMPACT ANALYSIS: PLASMA FRACTIONATION MARKET	65	
	TABLE 1	GLOBAL INFLATION RATE PROJECTION, 2021-2027 (% GROWTH)	66
	TABLE 2	US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)	66
	TABLE 3	US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)	66
3	EXECUTIVE SUMMARY	68	
	FIGURE 12	PLASMA FRACTIONATION MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)	68
	FIGURE 13	PLASMA FRACTIONATION MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)	69
	FIGURE 14	PLASMA FRACTIONATION MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)	69
	FIGURE 15	REGIONAL SNAPSHOT: PLASMA FRACTIONATION MARKET	70
4	PREMIUM INSIGHTS	71	
4.1	PLASMA FRACTIONATION MARKET OVERVIEW	71	
	FIGURE 16	GROWING USE OF IMMUNOGLOBULINS IN VARIOUS THERAPEUTIC AREAS TO DRIVE MARKET	71
4.2	NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT AND COUNTRY (2022)	72	
	FIGURE 17	IMMUNOGLOBULINS AND US DOMINATED NORTH AMERICAN PLASMA FRACTIONATION MARKET IN 2022	72
4.3	PLASMA FRACTIONATION MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)	73	
	FIGURE 18	IMMUNOGLOBULINS SEGMENT TO DOMINATE PLASMA FRACTIONATION MARKET DURING FORECAST PERIOD	73
4.4	PLASMA FRACTIONATION MARKET, BY END USER, 2022	73	
	FIGURE 19	HOSPITALS AND CLINICS SEGMENT COMMANDED LARGEST MARKET SHARE IN PLASMA FRACTIONATION MARKET IN 2022	73
4.5	PLASMA FRACTIONATION MARKET: REGIONAL GROWTH OPPORTUNITIES	74	
	FIGURE 20	ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN PLASMA FRACTIONATION MARKET FROM 2023 TO 2028	74
5	MARKET OVERVIEW	75	
5.1	INTRODUCTION	75	
	FIGURE 21	PLASMA FRACTIONATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	75
5.2	MARKET DYNAMICS	76	
	TABLE 4	PLASMA FRACTIONATION MARKET: IMPACT ANALYSIS	76
5.2.1	DRIVERS	76	
5.2.1.1	Growing use of immunoglobulins in various therapeutic areas	76	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 5	OFF-LABEL INDICATIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIG)	77
TABLE 6	ON-LABEL INDICATIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIG)	78
TABLE 7	NUMBER OF CLINICAL STUDIES ON IMMUNOGLOBULINS, BY COUNTRY/REGION (2020-2021)	79
TABLE 8	NUMBER OF PATIENTS TREATED FOR TOP 15 TARGET CONDITIONS IN UK	79
5.2.1.2	Strategic expansion of plasma collection centers/inventories by market players	80
5.2.1.3	Growing prevalence of respiratory diseases and Alpha-1-antitrypsin deficiency	81
5.2.2	RESTRAINTS	81
5.2.2.1	High costs and limited reimbursements for plasma-derived products	81
5.2.2.2	Market disruption caused by recombinant alternatives	82
5.2.3	OPPORTUNITIES	82
5.2.3.1	Government strategies for increasing regional self-sufficiency in plasma fractionation	82
5.2.4	CHALLENGES	83
5.2.4.1	Stringent government regulations for maintaining safety and quality of plasma-derived products	83
5.3	PRICING ANALYSIS	84
TABLE 9	AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS, BY KEY PLAYER, 2022 (USD)	84
TABLE 10	AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS, BY REGION, 2021 (USD)	84
5.4	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	85
FIGURE 22	REVENUE SHIFT AND NEW POCKETS FOR PLASMA FRACTIONATION PRODUCT PROVIDERS	85
5.5	VALUE CHAIN ANALYSIS	85
FIGURE 23	PROCEDURE OF PLASMA FRACTIONATION	86
FIGURE 24	VALUE CHAIN ANALYSIS: PLASMA FRACTIONATION MARKET	87
5.6	SUPPLY CHAIN ANALYSIS	87
FIGURE 25	SUPPLY CHAIN ANALYSIS: PLASMA FRACTIONATION MARKET	88
5.7	ECOSYSTEM MARKET MAP	89
FIGURE 26	ECOSYSTEM MARKET MAP: PLASMA FRACTIONATION MARKET	89
TABLE 11	ROLE IN ECOSYSTEM (SUPPLY SIDE/DEMAND SIDE): PLASMA FRACTIONATION MARKET	90
5.8	PATENT ANALYSIS	92
FIGURE 27	PATENT APPLICATIONS FOR PLASMA FRACTIONATION MARKET, JANUARY 2013-JULY 2023	92
5.9	KEY CONFERENCES AND EVENTS IN 2023-2024	93
TABLE 12	PLASMA FRACTIONATION MARKET: LIST OF CONFERENCES AND EVENTS IN 2023-2024	93
5.10	REGULATORY ANALYSIS	93
TABLE 13	NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	93
TABLE 14	EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	94
TABLE 15	ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	94
TABLE 16	LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	95
TABLE 17	MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	95
5.10.1	REGULATORY SCENARIO IN DIFFERENT COUNTRIES/REGIONS	95
5.11	PORTER'S FIVE FORCES ANALYSIS	97
TABLE 18	PORTER'S FIVE FORCES ANALYSIS: PLASMA FRACTIONATION MARKET	97
5.11.1	THREAT OF NEW ENTRANTS	97
5.11.2	THREAT OF SUBSTITUTES	97
5.11.3	BARGAINING POWER OF BUYERS	98
5.11.4	BARGAINING POWER OF SUPPLIERS	98
5.11.5	INTENSITY OF COMPETITIVE RIVALRY	98
5.12	TECHNOLOGY ANALYSIS	99
5.12.1	COHN'S COLD ETHANOL PLASMA FRACTIONATION	99
5.12.2	GEL FILTRATION PLASMA FRACTIONATION	99

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.12.3	HUMAN PLASMA FRACTIONATION BY POLYETHYLENE GLYCOL	99
5.12.4	PLASMA FRACTIONATION BY AMMONIUM SULFATE	99
5.12.5	PLASMA FRACTIONATION BY CENTRIFUGATION	100
5.12.6	DEPTH FILTRATION PLASMA FRACTIONATION	100
5.12.7	PLASMA FRACTIONATION BY CHROMATOGRAPHY	100
5.13	KEY STAKEHOLDERS AND BUYING CRITERIA	100
FIGURE 28	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PLASMA FRACTIONATION PRODUCTS	100
5.14	KEY BUYING CRITERIA, BY END USER	101
FIGURE 29	KEY BUYING CRITERIA OF END USERS IN PLASMA FRACTIONATION MARKET	101
5.15	PLASMA COLLECTION, BY VOLUME	101
5.15.1	US	101
5.15.2	CANADA	102
5.15.3	UK	102
5.15.4	JAPAN	102
5.15.5	INDIA	102
5.15.6	BRAZIL	103
5.16	PLASMA COLLECTION CENTERS	103
FIGURE 30	PLASMA COLLECTION CENTERS IN NORTH AMERICA, 2010-2021	103
TABLE 19	NUMBER OF PLASMA COLLECTION CENTERS, BY COMPANY, 2021-2022	104
6	PLASMA FRACTIONATION MARKET, BY PRODUCT	105
6.1	INTRODUCTION	106
TABLE 20	PLASMA FRACTIONATION MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	106
6.2	IMMUNOGLOBULINS	106
TABLE 21	INTRAVENOUS IMMUNOGLOBULINS (IVIG) VS. SUBCUTANEOUS IMMUNOGLOBULINS (SCIG) THERAPY	107
TABLE 22	PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY REGION, 2021-2028 (USD MILLION)	108
TABLE 23	NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2021-2028 (USD MILLION)	108
TABLE 24	EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2021-2028 (USD MILLION)	108
TABLE 25	ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2021-2028 (USD MILLION)	109
TABLE 26	LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2021-2028 (USD MILLION)	109
TABLE 27	MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2021-2028 (USD MILLION)	110
TABLE 28	PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2021-2028 (USD MILLION)	110
6.2.1	IVIG	110
6.2.1.1	Intravenous immunoglobulins segment to dominate plasma fractionation immunoglobulins market during study period	110
TABLE 29	IVIG OFFERED BY KEY PLAYERS	111
TABLE 30	IVIG MARKET, BY REGION, 2021-2028 (USD MILLION)	112
TABLE 31	IVIG MARKET, BY REGION, 2021-2028 (METRIC TONS)	113
TABLE 32	NORTH AMERICA: IVIG MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	113
TABLE 33	NORTH AMERICA: IVIG MARKET, BY COUNTRY, 2021-2028 (METRIC TONS)	113
TABLE 34	EUROPE: IVIG MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	114
TABLE 35	EUROPE: IVIG MARKET, BY COUNTRY, 2021-2028 (METRIC TONS)	114
TABLE 36	ASIA PACIFIC: IVIG MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	115
TABLE 37	ASIA PACIFIC: IVIG MARKET, BY COUNTRY, 2021-2028 (METRIC TONS)	115
TABLE 38	LATIN AMERICA: IVIG MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	115
TABLE 39	LATIN AMERICA: IVIG MARKET, BY COUNTRY, 2021-2028 (METRIC TONS)	116
TABLE 40	MIDDLE EAST & AFRICA: IVIG MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	116

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 41 MIDDLE EAST & AFRICA: IVIG MARKET, BY COUNTRY, 2021-2028 (METRIC TONS) 116

6.2.2 SCIG 117

6.2.2.1 Ease of self-administration and lower incidence of non-serious systemic adverse reactions to drive segment 117

TABLE 42 SCIG OFFERED BY KEY PLAYERS 117

TABLE 43 SCIG MARKET, BY REGION, 2021-2028 (USD MILLION) 118

TABLE 44 SCIG MARKET, BY REGION, 2021-2028 (METRIC TONS) 118

TABLE 45 NORTH AMERICA: SCIG MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 118

TABLE 46 NORTH AMERICA: SCIG MARKET, BY COUNTRY, 2021-2028 (METRIC TONS) 119

TABLE 47 EUROPE: SCIG MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 119

TABLE 48 EUROPE: SCIG MARKET, BY COUNTRY, 2021-2028 (METRIC TONS) 119

TABLE 49 ASIA PACIFIC: SCIG MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 120

TABLE 50 ASIA PACIFIC: SCIG MARKET, BY COUNTRY, 2021-2028 (METRIC TONS) 120

TABLE 51 LATIN AMERICA: SCIG MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 120

TABLE 52 LATIN AMERICA: SCIG MARKET, BY COUNTRY, 2021-2028 (METRIC TONS) 121

TABLE 53 MIDDLE EAST & AFRICA: SCIG MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 121

TABLE 54 MIDDLE EAST & AFRICA: SCIG MARKET, BY COUNTRY, 2021-2028 (METRIC TONS) 121

6.2.3 OTHER IMMUNOGLOBULINS 122

TABLE 55 OTHER IMMUNOGLOBULINS OFFERED BY KEY PLAYERS 122

TABLE 56 OTHER IMMUNOGLOBULINS MARKET, BY REGION, 2021-2028 (USD MILLION) 124

TABLE 57 OTHER IMMUNOGLOBULINS MARKET, BY REGION, 2021-2028 (METRIC TONS) 124

TABLE 58 NORTH AMERICA: OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 125

TABLE 59 NORTH AMERICA: OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2021-2028 (METRIC TONS) 125

TABLE 60 EUROPE: OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 125

TABLE 61 EUROPE: OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2021-2028 (METRIC TONS) 126

TABLE 62 ASIA PACIFIC: OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 126

TABLE 63 ASIA PACIFIC: OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2021-2028 (METRIC TONS) 127

TABLE 64 LATIN AMERICA: OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 127

TABLE 65 LATIN AMERICA: OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2021-2028 (METRIC TONS) 127

TABLE 66 MIDDLE EAST & AFRICA: OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 128

TABLE 67 MIDDLE EAST & AFRICA: OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2021-2028 (METRIC TONS) 128

6.3 COAGULATION FACTOR CONCENTRATES 128

TABLE 68 PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY REGION, 2021-2028 (USD MILLION) 129

TABLE 69 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2021-2028 (USD MILLION) 129

TABLE 70 EUROPE: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2021-2028 (USD MILLION) 130

TABLE 71 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2021-2028 (USD MILLION) 130

TABLE 72 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2021-2028 (USD MILLION) 131

TABLE 73 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2021-2028 (USD MILLION) 131

TABLE 74 PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2021-2028 (USD MILLION) 131

6.3.1 FACTOR VIII 132

6.3.1.1 Factor VIII held largest share of coagulation factor concentrates market in 2022 132

TABLE 75 FACTOR VIII OFFERED BY KEY PLAYERS 132

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 76 □ FACTOR VIII MARKET, BY REGION, 2021-2028 (USD MILLION) □ 133

TABLE 77 □ FACTOR VIII MARKET, BY REGION, 2021-2028 (MILLION IU) □ 133

TABLE 78 □ NORTH AMERICA: FACTOR VIII MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 133

TABLE 79 □ NORTH AMERICA: FACTOR VIII MARKET, BY COUNTRY, 2021-2028 (MILLION IU) □ 134

TABLE 80 □ EUROPE: FACTOR VIII MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 134

TABLE 81 □ EUROPE: FACTOR VIII MARKET, BY COUNTRY, 2021-2028 (MILLION IU) □ 134

TABLE 82 □ ASIA PACIFIC: FACTOR VIII MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 135

TABLE 83 □ ASIA PACIFIC: FACTOR VIII MARKET, BY COUNTRY, 2021-2028 (MILLION IU) □ 135

TABLE 84 □ LATIN AMERICA: FACTOR VIII MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 135

TABLE 85 □ LATIN AMERICA: FACTOR VIII MARKET, BY COUNTRY, 2021-2028 (MILLION IU) □ 136

TABLE 86 □ MIDDLE EAST & AFRICA: FACTOR VIII MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 136

TABLE 87 □ MIDDLE EAST & AFRICA: FACTOR VIII MARKET, BY COUNTRY, 2021-2028 (MILLION IU) □ 136

6.3.2 □ FACTOR IX □ 137

6.3.2.1 □ Routine use of human plasma-derived factor IX concentrates in hemophilia treatment to drive segment □ 137

TABLE 88 □ FACTOR IX OFFERED BY KEY PLAYERS □ 137

TABLE 89 □ FACTOR IX MARKET, BY REGION, 2021-2028 (USD MILLION) □ 138

TABLE 90 □ FACTOR IX MARKET, BY REGION, 2021-2028 (MILLION IU) □ 138

TABLE 91 □ NORTH AMERICA: FACTOR IX MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 138

TABLE 92 □ NORTH AMERICA: FACTOR IX MARKET, BY COUNTRY, 2021-2028 (MILLION IU) □ 139

TABLE 93 □ EUROPE: FACTOR IX MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 139

TABLE 94 □ EUROPE: FACTOR IX MARKET, BY COUNTRY, 2021-2028 (MILLION IU) □ 139

TABLE 95 □ ASIA PACIFIC: FACTOR IX MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 140

TABLE 96 □ ASIA PACIFIC: FACTOR IX MARKET, BY COUNTRY, 2021-2028 (MILLION IU) □ 140

TABLE 97 □ LATIN AMERICA: FACTOR IX MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 140

TABLE 98 □ LATIN AMERICA: FACTOR IX MARKET, BY COUNTRY, 2021-2028 (MILLION IU) □ 141

TABLE 99 □ MIDDLE EAST & AFRICA: FACTOR IX MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 141

TABLE 100 □ MIDDLE EAST & AFRICA: FACTOR IX MARKET, BY COUNTRY, 2021-2028 (MILLION IU) □ 141

6.3.3 □ VON WILLEBRAND FACTOR □ 142

6.3.3.1 □ Increasing prevalence and early diagnosis of hemophilia to drive segment □ 142

TABLE 101 □ VON WILLEBRAND FACTOR OFFERED BY KEY PLAYERS □ 142

TABLE 102 □ VON WILLEBRAND FACTOR MARKET, BY REGION, 2021-2028 (USD MILLION) □ 143

TABLE 103 □ VON WILLEBRAND FACTOR MARKET, BY REGION, 2021-2028 (MILLION LITER) □ 143

TABLE 104 □ NORTH AMERICA: VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 143

TABLE 105 □ NORTH AMERICA: VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2021-2028 (MILLION IU) □ 144

TABLE 106 □ EUROPE: VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 144

TABLE 107 □ EUROPE: VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2021-2028 (MILLION IU) □ 144

TABLE 108 □ ASIA PACIFIC: VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 145

TABLE 109 □ ASIA PACIFIC: VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2021-2028 (MILLION IU) □ 145

TABLE 110 □ LATIN AMERICA: VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 146

TABLE 111 □ LATIN AMERICA: VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2021-2028 (MILLION IU) □ 146

TABLE 112 □ MIDDLE EAST & AFRICA: VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 146

TABLE 113 □ MIDDLE EAST & AFRICA: VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2021-2028 (MILLION IU) □ 147

6.3.4 □ PROTHROMBIN COMPLEX CONCENTRATES □ 147

6.3.4.1 □ Advantages of prothrombin complex concentrate over fresh frozen plasma to drive segment □ 147

TABLE 114 □ PROTHROMBIN COMPLEX CONCENTRATES OFFERED BY KEY PLAYERS □ 147

TABLE 115 □ PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY REGION, 2021-2028 (USD MILLION) □ 148

TABLE 116 □ PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY REGION, 2021-2028 (MILLION LITER) □ 148

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 117 NORTH AMERICA: PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 148

TABLE 118 NORTH AMERICA: PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (MILLION IU) 149

TABLE 119 EUROPE: PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 149

TABLE 120 EUROPE: PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (MILLION IU) 149

TABLE 121 ASIA PACIFIC: PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 150

TABLE 122 ASIA PACIFIC: PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (MILLION IU) 150

TABLE 123 LATIN AMERICA: PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 151

TABLE 124 LATIN AMERICA: PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (MILLION IU) 151

TABLE 125 MIDDLE EAST & AFRICA: PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 151

TABLE 126 MIDDLE EAST & AFRICA: PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (MILLION IU) 152

6.3.5 FIBRINOGEN CONCENTRATES 152

6.3.5.1 Better safety profile, greater accuracy, and higher speed of administration to drive segment 152

TABLE 127 FIBRINOGEN CONCENTRATES OFFERED BY KEY PLAYERS 152

TABLE 128 FIBRINOGEN CONCENTRATES MARKET, BY REGION, 2021-2028 (USD MILLION) 153

TABLE 129 FIBRINOGEN CONCENTRATES MARKET, BY REGION, 2021-2028 (METRIC TONS) 153

TABLE 130 NORTH AMERICA: FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 153

TABLE 131 NORTH AMERICA: FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (METRIC TONS) 154

TABLE 132 EUROPE: FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 154

TABLE 133 EUROPE: FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (METRIC TONS) 154

TABLE 134 ASIA PACIFIC: FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 155

TABLE 135 ASIA PACIFIC: FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (METRIC TONS) 155

TABLE 136 LATIN AMERICA: FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 156

TABLE 137 LATIN AMERICA: FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (METRIC TONS) 156

TABLE 138 MIDDLE EAST & AFRICA: FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 156

TABLE 139 MIDDLE EAST & AFRICA: FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (METRIC TONS) 157

6.3.6 FACTOR XIII 157

6.3.6.1 Applications in treating rare bleeding disorders and preventing surgical bleeding to drive segment 157

TABLE 140 FACTOR XIII OFFERED BY KEY PLAYERS 157

TABLE 141 FACTOR XIII MARKET, BY REGION, 2021-2028 (USD MILLION) 157

TABLE 142 FACTOR XIII, BY REGION, 2021-2028 (MILLION IU) 158

TABLE 143 NORTH AMERICA: FACTOR XIII MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 158

TABLE 144 NORTH AMERICA: FACTOR XIII MARKET, BY COUNTRY, 2021-2028 (MILLION IU) 158

TABLE 145 EUROPE: FACTOR XIII MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 159

TABLE 146 EUROPE FACTOR XIII MARKET, BY COUNTRY, 2021-2028 (MILLION IU) 159

TABLE 147 ASIA PACIFIC: FACTOR XIII MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 160

TABLE 148 ASIA PACIFIC: FACTOR XIII MARKET, BY COUNTRY, 2021-2028 (MILLION IU) 160

TABLE 149 LATIN AMERICA: FACTOR XIII MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 161

TABLE 150 LATIN AMERICA: FACTOR XIII MARKET, BY COUNTRY, 2021-2028 (MILLION IU) 161

TABLE 151 MIDDLE EAST & AFRICA: FACTOR XIII MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 161

TABLE 152 MIDDLE EAST & AFRICA: FACTOR XIII MARKET, BY COUNTRY, 2021-2028 (MILLION IU) 162

6.3.7 OTHER COAGULATION FACTOR CONCENTRATES 162

TABLE 153 OTHER COAGULATION FACTOR CONCENTRATES MARKET, BY REGION, 2021-2028 (USD MILLION) 162

TABLE 154 NORTH AMERICA: OTHER COAGULATION FACTOR CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 163

TABLE 155 EUROPE: OTHER COAGULATION FACTOR CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 163

TABLE 156 ASIA PACIFIC: OTHER COAGULATION FACTOR CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 164

TABLE 157 LATIN AMERICA: OTHER COAGULATION FACTOR CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 164

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 158 MIDDLE EAST & AFRICA: OTHER COAGULATION FACTOR CONCENTRATES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 165

6.4 ALBUMIN 165

6.4.1 RISING DEMAND IN MAINTAINING ONCOTIC PRESSURE AND CONDUCTING MEDICAL TREATMENTS TO DRIVE MARKET 165

TABLE 159 ALBUMIN OFFERED BY KEY PLAYERS 166

TABLE 160 PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY REGION, 2021-2028 (USD MILLION) 167

TABLE 161 PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY REGION, 2021-2028 (MILLION LITER) 167

TABLE 162 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2021-2028 (USD MILLION) 167

TABLE 163 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2021-2028 (METRIC TONS) 168

TABLE 164 EUROPE: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2021-2028 (USD MILLION) 168

TABLE 165 EUROPE: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2021-2028 (METRIC TONS) 168

TABLE 166 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2021-2028 (USD MILLION) 169

TABLE 167 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2021-2028 (METRIC TONS) 169

TABLE 168 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2021-2028 (USD MILLION) 170

TABLE 169 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2021-2028 (METRIC TONS) 170

TABLE 170 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2021-2028 (USD MILLION) 170

TABLE 171 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2021-2028 (METRIC TONS) 171

6.5 PROTEASE INHIBITORS 171

6.5.1 RISING PREVALENCE OF COPD AND OTHER RESPIRATORY DISEASES GLOBALLY TO DRIVE MARKET 171

TABLE 172 PROTEASE INHIBITORS OFFERED BY KEY PLAYERS 171

TABLE 173 PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY REGION, 2021-2028 (USD MILLION) 172

TABLE 174 PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY REGION, 2021-2028 (MILLION IU) 172

TABLE 175 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2021-2028 (USD MILLION) 173

TABLE 176 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2021-2028 (MILLION IU) 173

TABLE 177 EUROPE: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2021-2028 (USD MILLION) 173

TABLE 178 EUROPE: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2021-2028 (MILLION IU) 174

TABLE 179 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2021-2028 (USD MILLION) 174

TABLE 180 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2021-2028 (MILLION IU) 175

TABLE 181 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2021-2028 (USD MILLION) 175

TABLE 182 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2021-2028 (MILLION IU) 175

TABLE 183 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2021-2028 (USD MILLION) 176

TABLE 184 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2021-2028 (MILLION IU) 176

6.6 OTHER PLASMA PRODUCTS 176

TABLE 185 PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY REGION, 2021-2028 (USD MILLION) 177

TABLE 186 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2021-2028 (USD MILLION) 177

TABLE 187 EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2021-2028 (USD MILLION) 177

TABLE 188 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2021-2028 (USD MILLION) 178

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 189 □ LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2021-2028 (USD MILLION) □ 178

TABLE 190 □ MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2021-2028 (USD MILLION) □ 179

7 □ PLASMA FRACTIONATION MARKET, BY APPLICATION □ 180

7.1 □ INTRODUCTION □ 181

TABLE 191 □ PLASMA FRACTIONATION MARKET, BY APPLICATION, 2021-2028 (USD MILLION) □ 181

7.2 □ NEUROLOGY □ 181

7.2.1 □ RISING PREVALENCE OF AGE-RELATED NEUROLOGICAL DISORDERS TO DRIVE MARKET □ 181

TABLE 192 □ DISABILITY-ADJUSTED LIFE YEARS (DALYS) FOR NEUROLOGICAL DISORDERS AND PROJECTED PERCENTAGE (2005 VS. 2015 VS. 2030) □ 182

TABLE 193 □ PLASMA-DERIVED PRODUCTS AND APPLICATIONS IN NEUROLOGY □ 183

TABLE 194 □ PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY REGION, 2021-2028 (USD MILLION) □ 183

TABLE 195 □ NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 184

TABLE 196 □ EUROPE: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, 2021-2028 (USD MILLION) □ 184

TABLE 197 □ ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 185

TABLE 198 □ LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 185

TABLE 199 □ MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 186

7.3 □ IMMUNOLOGY □ 186

7.3.1 □ ADVANCEMENTS IN GENETICS RESEARCH AND NOVEL THERAPEUTIC STRATEGIES TO DRIVE MARKET □ 186

TABLE 200 □ PHYSICIAN-REPORTED PREVALENCE OF PRIMARY IMMUNODEFICIENCY DISEASES AMONG PATIENTS, BY REGION, 2013-2021 □ 187

TABLE 201 □ LIST OF FDA-APPROVED INDICATIONS FOR IMMUNOGLOBULINS IN IMMUNOLOGY □ 188

TABLE 202 □ DIAGNOSIS DISTRIBUTION OF DIFFERENT CATEGORIES OF PRIMARY IMMUNODEFICIENCY DISEASES □ 189

TABLE 203 □ PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN IMMUNOLOGY □ 189

TABLE 204 □ PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY REGION, 2021-2028 (USD MILLION) □ 190

TABLE 205 □ NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 190

TABLE 206 □ EUROPE: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, 2021-2028 (USD MILLION) □ 190

TABLE 207 □ ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 191

TABLE 208 □ LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 191

TABLE 209 □ MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 192

7.4 □ HEMATOLOGY □ 192

7.4.1 □ GROWING NUMBER OF HEMOPHILIA PATIENTS TO DRIVE DEMAND FOR COAGULATION FACTORS □ 192

TABLE 210 □ NUMBER OF IDENTIFIED PATIENTS, BY INDICATION, 2021 □ 192

FIGURE 31 □ DISTRIBUTION OF HEMOPHILIA PATIENTS, BY REGION, 2022 □ 193

TABLE 211 □ PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY REGION, 2021-2028 (USD MILLION) □ 194

TABLE 212 □ NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 194

TABLE 213 □ EUROPE: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, 2021-2028 (USD MILLION) □ 194

TABLE 214 □ ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 195

TABLE 215 □ LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 195

TABLE 216 □ MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 196

7.5 □ CRITICAL CARE □ 196

7.5.1 □ INCREASING OFF-LABEL USE OF ALBUMIN TO DRIVE DEMAND FOR PLASMA-DERIVED CRITICAL CARE PRODUCTS □ 196

TABLE 217 □ PLASMA-DERIVED PRODUCTS AND APPLICATIONS IN CRITICAL CARE □ 197

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 218	PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY REGION, 2021-2028 (USD MILLION)	197
TABLE 219	NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2021-2028 (USD MILLION)	198
TABLE 220	EUROPE: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, 2021-2028 (USD MILLION)	198
TABLE 221	ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2021-2028 (USD MILLION)	199
TABLE 222	LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2021-2028 (USD MILLION)	199
TABLE 223	MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2021-2028 (USD MILLION)	200
7.6	PULMONOLOGY	200
7.6.1	RISING PREVALENCE OF ALPHA-1-ANTITRYPSIN DEFICIENCY AND COPD TO DRIVE MARKET	200
TABLE 224	PLASMA-DERIVED PRODUCTS AND APPLICATIONS IN PULMONOLOGY	201
TABLE 225	PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY REGION, 2021-2028 (USD MILLION)	201
TABLE 226	NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)	201
TABLE 227	EUROPE: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, 2021-2028 (USD MILLION)	202
TABLE 228	ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)	202
TABLE 229	LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)	203
TABLE 230	MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)	203
7.7	HEMATO-ONCOLOGY	203
7.7.1	RISING NUMBER OF BLOOD CANCER PATIENTS TO DRIVE MARKET	203
TABLE 231	PLASMA-DERIVED PRODUCTS AND APPLICATIONS IN HEMATO-ONCOLOGY	204
TABLE 232	PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY REGION, 2021-2028 (USD MILLION)	204
TABLE 233	NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)	204
TABLE 234	EUROPE: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, 2021-2028 (USD MILLION)	205
TABLE 235	ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)	205
TABLE 236	LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)	206
TABLE 237	MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)	206
7.8	RHEUMATOLOGY	206
7.8.1	INCREASING PREVALENCE OF RHEUMATIC ARTHRITIS IN DEVELOPED COUNTRIES TO DRIVE MARKET	206
TABLE 238	PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY REGION, 2021-2028 (USD MILLION)	207
TABLE 239	NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)	207
TABLE 240	EUROPE: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, 2021-2028 (USD MILLION)	207
TABLE 241	ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)	208
TABLE 242	LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)	208
TABLE 243	MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)	209
7.9	OTHER APPLICATIONS	209
TABLE 244	PLASMA-DERIVED PRODUCTS FOR OTHER APPLICATIONS	210
TABLE 245	PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)	210
TABLE 246	NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	211
TABLE 247	EUROPE: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, 2021-2028 (USD MILLION)	211
TABLE 248	ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	212
TABLE 249	LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)	212

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

MILLION) 212

TABLE 250 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 213

8 PLASMA FRACTIONATION MARKET, BY END USER 214

8.1 INTRODUCTION 215

TABLE 251 PLASMA FRACTIONATION MARKET, BY END USER, 2021-2028 (USD MILLION) 215

8.2 HOSPITALS AND CLINICS 215

8.2.1 GROWING NUMBER OF SURGERIES AND INCREASING OFF-LABEL USE OF IMMUNOGLOBULINS TO DRIVE MARKET 215

TABLE 252 PLASMA FRACTIONATION MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021-2028 (USD MILLION) 216

TABLE 253 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION) 216

TABLE 254 EUROPE: PLASMA FRACTIONATION MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION) 217

TABLE 255 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION) 217

TABLE 256 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS AND CLINICS, 2021-2028 (USD MILLION) 218

TABLE 257 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION) 218

8.3 CLINICAL RESEARCH LABORATORIES 218

8.3.1 INCREASING CLINICAL STUDIES ON NEW INDICATIONS FOR PLASMA-DERIVED PRODUCTS TO DRIVE MARKET 218

TABLE 258 PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY REGION, 2021-2028 (USD MILLION) 219

TABLE 259 NORTH AMERICA: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2021-2028 (USD MILLION) 219

TABLE 260 EUROPE: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2021-2028 (USD MILLION) 220

TABLE 261 ASIA PACIFIC: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2021-2028 (USD MILLION) 220

TABLE 262 LATIN AMERICA: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, 2021-2028 (USD MILLION) 221

TABLE 263 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2021-2028

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) - Global Forecast to 2028**

Market Report | 2023-09-05 | 374 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code\*

Country\*

Date

2026-03-02

Signature

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)